AI-native personal health companies using continuous biomarker data

Here are 10 early-to-growth stage, AI-native personal health companies leveraging continuous biomarker data, avoiding the over-exposed unicorns (like Oura, Whoop, or Levels).

1. January AI — Trains an AI model on a user’s initial Continuous Glucose Monitor (CGM) data to accurately predict future glucose spikes without requiring the user to wear a physical sensor long-term. Why it fits: Series B; strong AI-native thesis backed by a16z and Marc Benioff, showing high signal in transitioning metabolic health from hardware-dependent tracking to predictive software.

2. Vively — An Australian startup combining CGM data with an AI coaching layer to provide real-time, personalized diet and lifestyle interventions for metabolic health. Why it fits: Seed stage; strong early consumer traction in the APAC market, proving that the AI-driven metabolic health model can scale in geographies where incumbents are less saturated.

3. Aktiia — Uses optical sensors and proprietary AI algorithms to provide continuous, cuffless blood pressure monitoring via a lightweight wristband. Why it fits: Series A/B; incredible clinical validation signal (CE marked) addressing a massive gap in continuous cardiovascular data, moving hypertension management from point-in-time to continuous.

4. Nix Biosensors — A wearable patch that continuously analyzes sweat biomarkers to provide AI-driven, real-time hydration and electrolyte loss insights. Why it fits: Early commercial stage; strong signal in both elite sports performance and industrial safety, proving willingness-to-pay for continuous sweat data outside of clinical settings.

5. Epicore Biosystems — Develops microfluidic wearable patches that continuously track sweat biomarkers and skin temperature, analyzed via a predictive AI engine. Why it fits: Series A; strong B2B2C traction with major corporate partnerships (e.g., Chevron, PepsiCo) for industrial worker health, validating the enterprise market for continuous physiological monitoring.

6. Biolinq — Developing a wearable patch that uses an array of microscopic, intradermal electrochemical sensors to continuously measure glucose and other metabolic biomarkers. Why it fits: Series B; deep-tech signal with backing from the JDRF T1D Fund, pushing the hardware frontier beyond traditional needle-based CGMs to enable richer, multi-biomarker AI analytics.

7. Biobeat — AI-powered wearable monitors (patch and watch form factors) that continuously track 14+ cardiopulmonary biomarkers, including stroke volume and blood oxygen. Why it fits: Growth stage; strong regulatory signal with multiple FDA clearances, successfully bridging the gap between hospital-grade continuous monitoring and at-home personal health.

8. X-trodes — Flexible, smart skin patches that provide continuous, wireless electrophysiological monitoring (EMG, ECG, EEG) paired with machine learning analytics. Why it fits: Seed/Series A stage; strong deep-tech signal spinning out of Tel Aviv University, miniaturizing and consumerizing continuous neurological and muscular data for at-home use.

9. NuraLogix — Uses Transdermal Optical Imaging and affective AI to extract continuous facial blood flow data from standard smartphone cameras to predict metabolic and cardiovascular risks. Why it fits: Series B; highly scalable, software-only approach to continuous biomarker tracking, showing strong traction in B2B telehealth and insurance integrations.

10. PKvitality — Developing K'Watch, a smartwatch that uses a consumable micro-needle patch on the underside to continuously monitor glucose and lactate levels. Why it fits: Clinical trials stage; strong signal in the athletic and diabetic communities by combining continuous, sub-dermal biomarker extraction with a socially acceptable, standard smartwatch form factor.

***

2 Most Interesting White-Space Gaps

1. Continuous Female Endocrinology: The market is saturated with continuous metabolic (glucose) and cardiovascular (HRV, BP) monitors, but tracking female hormones (estrogen, progesterone, LH, FSH) still relies on point-in-time, manual tests (urine strips or blood draws). There is a massive white space for a continuous, non-invasive biomarker wearable paired with AI to manage menopause, PCOS, and fertility in real-time.

2. Real-Time Cortisol & Neurotransmitter Tracking: Current "stress tracking" wearables rely entirely on proxy metrics (HRV, resting heart rate, skin temperature). There is a glaring gap for continuous, microfluidic or intradermal monitoring of actual stress biomarkers (like cortisol or adrenaline) paired with an AI agent that can deliver real-time, context-aware mental health and behavioral interventions.